NCT02844335

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced breast cancer.

Detailed description

By enrolling patients with breast cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for advanced breast cancer. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

Conditions

• Breast Cancer Recurrent

Interventions

Type	Name	Description
DEVICE	Cryosurgery	Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
BIOLOGICAL	NK immunotherapy	Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)

Timeline

• Start date: 2016-07-01
• Primary completion: 2017-07-01
• Completion: 2019-07-01
• First posted: 2016-07-26
• Last updated: 2019-09-12

Locations

1 site across 1 country: China